Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines

Targeted protein degradation represents a transformative shift in pharmacology, moving beyond traditional binary drug-protein interactions to utilize the cell's own machinery for therapeutic effect. Tim Shannon, a general partner at Canaan Partners and former physician, details his journey from academic medicine to biotech leadership, highlighting the development of Arvinas and Halda Therapeutics. These companies pioneered PROTACs and Riptacs, respectively, leveraging induced proximity to address previously "undruggable" targets and overcome tumor resistance. By bringing disease-causing proteins into complex with essential cellular components, these modalities trigger apoptosis, offering a robust mechanism for treating complex, heterogeneous cancers. Successful biotech innovation requires balancing scientific novelty with rigorous business strategy, as even groundbreaking modalities like targeted degraders demand careful patient stratification and a deep understanding of tumor biology to achieve clinical success and sustainable commercial viability.